292 related articles for article (PubMed ID: 31267167)
1. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():265-282. PubMed ID: 31267167
[TBL] [Abstract][Full Text] [Related]
2. Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis.
Honda A; Salen G; Matsuzaki Y; Batta AK; Xu G; Hirayama T; Tint GS; Doy M; Shefer S
J Lipid Res; 2005 Feb; 46(2):287-96. PubMed ID: 15576845
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
4. Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report.
Koyama S; Okabe Y; Suzuki Y; Igari R; Sato H; Iseki C; Tanji K; Suzuki K; Ohta Y
BMC Neurol; 2022 May; 22(1):193. PubMed ID: 35614401
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G; Steiner RD
J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
[TBL] [Abstract][Full Text] [Related]
6. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
Weissfeld T; Ratliff J
J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
Mignarri A; Magni A; Del Puppo M; Gallus GN; Björkhem I; Federico A; Dotti MT
J Inherit Metab Dis; 2016 Jan; 39(1):75-83. PubMed ID: 26153518
[TBL] [Abstract][Full Text] [Related]
8. Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27(-/-) mice and CTX.
Honda A; Salen G; Matsuzaki Y; Batta AK; Xu G; Leitersdorf E; Tint GS; Erickson SK; Tanaka N; Shefer S
J Lipid Res; 2001 Feb; 42(2):291-300. PubMed ID: 11181760
[TBL] [Abstract][Full Text] [Related]
9. Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.
Koyama S; Sekijima Y; Ogura M; Hori M; Matsuki K; Miida T; Harada-Shiba M
J Atheroscler Thromb; 2021 Sep; 28(9):905-925. PubMed ID: 33967188
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis.
Salen G; Batta AK; Tint GS; Shefer S
Metabolism; 1994 Aug; 43(8):1018-22. PubMed ID: 8052141
[TBL] [Abstract][Full Text] [Related]
11. Chenodeoxycholic acid (CDCA) treatment during pregnancy in women with cerebrotendinous xanthomatosis (CTX): Lessons learned from 19 pregnancies.
Zaccai TCF; Hassin-Baer S; Kfir NC; Duell PB; Neerhof M; Sloma R; Roitman M; Kisanuki YY; Verrips A; DeBarber AE
Genet Med; 2024 May; 26(5):101086. PubMed ID: 38288684
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Huidekoper HH; Vaz FM; Verrips A; Bosch AM
Eur J Pediatr; 2016 Jan; 175(1):143-6. PubMed ID: 26156051
[TBL] [Abstract][Full Text] [Related]
13. The wide spectrum of cerebrotendinous xanthomatosis: Case report of a rare but treatable disease.
Rosafio F; Cavallieri F; Guaraldi P; Taroni F; Nichelli PF; Mandrioli J
Clin Neurol Neurosurg; 2016 Apr; 143():1-3. PubMed ID: 26874936
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
15. The Pharmacology of Bile Acids and Their Receptors.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.
Ito S; Kuwabara S; Sakakibara R; Oki T; Arai H; Oda S; Hattori T
J Neurol Sci; 2003 Dec; 216(1):179-82. PubMed ID: 14607320
[TBL] [Abstract][Full Text] [Related]
17. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
Keren Z; Falik-Zaccai TC
Pediatr Endocrinol Rev; 2009 Sep; 7(1):6-11. PubMed ID: 19696711
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
Kuriyama M; Tokimura Y; Fujiyama J; Utatsu Y; Osame M
J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
[TBL] [Abstract][Full Text] [Related]
19. Late-onset Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene.
Sasamura A; Akazawa S; Haraguchi A; Horie I; Ando T; Abiru N; Takei H; Nittono H; Une M; Kurosawa T; Murai T; Naruse H; Nakayama T; Kotani K; Remaley AT; Kawakami A
Intern Med; 2018 Jun; 57(11):1611-1616. PubMed ID: 29434128
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
